Dengue

Why in News?

India’s first indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec, has entered Phase-3 clinical trials. If successful, it could become India’s first licensed dengue vaccine, addressing a critical gap in public health preparedness.

About Dengue

• Pathogen: Caused by the dengue virus (DENV) of the Flavivirus genus, with four serotypes (DENV-1 to DENV-4).
• Transmission: Spread by the bite of infected female Aedes aegypti mosquitoes (also vectors for Zika and chikungunya).
• Symptoms:
  • Mild: High fever, headache, muscle/joint pain (“break-bone fever”), rash.
  • Severe: Dengue Hemorrhagic Fever (DHF) or Dengue Shock Syndrome (DSS), leading to plasma leakage, organ failure, or death.
• Global Burden:
  • 100+ countries affected, including India; 390 million infections/year worldwide.
  • India reports ~1–2 lakh cases annually, with peaks during monsoons.

Challenges in Dengue Management

1. Complex Immunity:
   • Infection with one serotype does not confer immunity to others; subsequent infections raise the risk of severe dengue due to antibody-dependent enhancement (ADE).
2. Vector Control:
   • Aedes mosquitoes breed in stagnant water (e.g., urban water containers), making eradication difficult.
3. Diagnosis & Treatment:
   • No specific antiviral drugs; treatment is supportive (hydration, fever management).
   • Delayed diagnosis due to overlapping symptoms with malaria/chikungunya.
4. Vaccine Development:
   • Previous vaccines like Dengvaxia (CYD-TDV) faced limitations (efficacy varies by serotype and prior exposure).

DengiAll Vaccine: Significance

• Tetravalent Design: Targets all four dengue serotypes, reducing ADE risks.
• Indigenous Development: Aligns with Atmanirbhar Bharat in biotech; reduces dependency on imports.
• Phase-3 Trials:
  • Involves large-scale testing across multiple sites to assess efficacy and safety.
  • Success could pave the way for DCGI approval and public health deployment.

Global Dengue Vaccines

1. Dengvaxia (Sanofi Pasteur):
   • Licensed in 20+ countries but not in India; recommended only for seropositive individuals.
2. Qdenga (TAK-003):
   • Approved in the EU, UK, and Indonesia (2022); shows 80% efficacy against symptomatic dengue.
3. TV003/TV005 (Butantan/NIH):
   • Under trial; single-dose tetravalent vaccine with promising results.

India’s Dengue Control Initiatives

1. National Vector Borne Disease Control Programme (NVBDCP):
   • Focuses on vector control (fogging, larvicidal measures) and public awareness.
2. National Dengue Day (May 16): Promotes prevention and community mobilization.
3. Diagnostic Infrastructure:
   • ELISA-based NS1 antigen and IgM antibody tests for early detection.
4. Research:
   • Institutions like ICMR and National Institute of Virology (NIV) study dengue epidemiology and vaccine development.

Strategic Importance of DengiAll

1. Public Health Impact: Reduce morbidity/mortality, especially in children.
2. Economic Benefit: Cut healthcare costs (India spends ₹6,000–₹10,000 crore annually on dengue management).
3. Global Leadership: Position India as a vaccine innovator for tropical diseases.

Conclusion:
The DengiAll vaccine trial represents a milestone in India’s fight against dengue. Coupled with robust vector control and public awareness, it could significantly reduce the disease burden, aligning with SDG 3 (Good Health) and India’s biotech ambitions.

UPSC Focus Areas

1. Vaccine Development: Link to Make in India and pandemic preparedness.
2. Dengue Epidemiology: Role of climate change/urbanization in disease spread.
3. Public Health Policies: NVBDCP’s effectiveness and challenges.
4. Science & Tech: Mechanism of tetravalent vaccines vs. ADE risks.
5. Global Comparisons: India’s progress vs. Brazil/Indonesia in dengue control.